HLA-A*2402-Restricted URLC10-KOC1-VEGFR1-VEGFR2 Multipeptide Vaccine

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from URLC10 (up-regulated lung cancer 10 or CO16); KOC1 (IGF II mRNA Binding Protein 3); and vascular endothelial growth factor receptors (VEGFRs) 1 and 2. Upon administration, this multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URL10-, KOC1-, VEGFR1- and VEGFR2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.